Holen Sie sich die Stockscreener-App
2.69
1.89%
0.05
Vorhandelsmarkt:
2.66
-0.03
-1.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ACHV?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.64
Offen:
$2.66
24-Stunden-Volumen:
1.13M
Relative Volume:
1.53
Marktkapitalisierung:
$93.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.94M
KGV:
-2.4234
EPS:
-1.11
Netto-Cashflow:
$-24.95M
1W Leistung:
+13.50%
1M Leistung:
-13.23%
6M Leistung:
-12.38%
1J Leistung:
-44.54%
1-Tages-Spanne:
$2.60
$2.7693
1-Wochen-Bereich:
$2.25
$2.85
52-Wochen-Spanne:
$1.84
$5.31
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Firmenname
Achieve Life Sciences Inc
Sektor
Branche
Telefon
425-686-1500
Adresse
22722 29TH DR. SE, SEATTLE, BC
Vergleichen Sie ACHV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
2.69 | 117.75M | 0 | -32.94M | -24.95M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.81 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.16 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Strong Buy |
| 2023-05-10 | Bestätigt | Maxim Group | Buy |
| 2021-06-23 | Eingeleitet | Oppenheimer | Outperform |
Achieve Life Sciences Inc Aktie (ACHV) Neueste Nachrichten
What makes Achieve Life Sciences Inc. stock price move sharplyFree Discussion Group - Newser
How Achieve Life Sciences Inc. stock performs during market volatilityTop Growth Low Risk Stocks - Newser
Why Achieve Life Sciences Inc. stock attracts strong analyst attentionWealth Building Stock Portfolio - Newser
Company’s Banking Shares: Up -49.72% from 52-Week Low, But Can the Momentum Hold? - investchronicle.com
Omnicom, Achieve Life Sciences Partner for AI-Driven Launch of New Nicotine Dependence Treatment - MSN
Achieve Life Sciences: The AI-Powered Push to Redefine Smoking Cessation - AInvest
Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation - Seeking Alpha
Should You Hold Achieve Life Sciences (ACHV)? - Insider Monkey
ACHV: Achieve’s Busy Day - Yahoo Finance
Achieve Life Sciences (ACHV) Receives a Buy from Raymond James - The Globe and Mail
Achieve Life Sciences stock falls after pricing capital raise of $45M via securities offering - MSN
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities | ACHV Stock News - GuruFocus
Achieve Life Sciences, Inc.(NasdaqCM: ACHV) dropped from Russell 3000 Index - MarketScreener
Achieve Life Sciences, Inc.(NasdaqCM: ACHV) dropped from Russell 3000 Growth Index - MarketScreener
Achieve Life Sciences, Inc.(NasdaqCM: ACHV) dropped from Russell 2500 Index - MarketScreener
Bothell biotech firm plans $45 million public offering to advance smoking cessation drug - The Business Journals
Tech And Biotech Stocks Take A Dive Following Surprising Announcements - Finimize
Achieve Life Sciences (ACHV) Submits FDA Application for Smoking Cessation Drug | ACHV Stock News - GuruFocus
ACHV Gains Attention with Strategic Financial Moves | ACHV Stock News - GuruFocus
Achieve Life Sciences (ACHV) Launches $45 Million Stock Offering - GuruFocus
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation - The Manila Times
Achieve Life Sciences Announces Pricing of $45.0 Million Underwr - GuruFocus
Achieve Life Sciences announces proposed public offering; shares down nearly 13% - MSN
Achieve Life Sciences announces public offering to fund cytisinicline By Investing.com - Investing.com UK
Achieve Life Sciences Announces Submission of NDA to FDA - GlobeNewswire
Achieve Life Sciences names Omnicom as strategic partner for launch - Investing.com
Achieve adds vapers to smokers in targeting multi-billion dollar market - The Pharma Letter
Bank of America Corp DE Purchases 9,760 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
Institutional investors may adopt severe steps after Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) latest 15% drop adds to a year losses - simplywall.st
Owning 46% shares,institutional owners seem interested in Achieve Life Sciences, Inc. (NASDAQ:ACHV), - Yahoo
Squarepoint Ops LLC Buys Shares of 17,519 Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
achieve life sciences holds annual meeting with key votes By Investing.com - Investing.com India
Achieve Life Sciences Elects Board at Annual Meeting - TipRanks
achieve life sciences holds annual meeting with key votes - Investing.com
Achieve Life Sciences (NASDAQ:ACHV) Shares Pass Above 200 Day Moving Average – What’s Next? - Defense World
Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk (ACHV) - Seeking Alpha
Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Late-Stage Smoking Cessation Drug Developer Achieve Life Sciences Sets Key Jefferies Conference Presentation - Stock Titan
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Shares Purchased by Northern Trust Corp - Defense World
Shay Capital LLC Sells 425,000 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) - MarketBeat
ACHV: New Insights from ORCA-3 Study to Be Shared at 2025 Conference | ACHV Stock News - GuruFocus
Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake | ACHV Stock News - GuruFocus
Achieve Life Sciences to Present Phase 3 Study Findings on Cytisinicline for Smoking Cessation at 2025 ATS Conference - Nasdaq
Achieve Life Sciences to Present New Data at the 2025 ATS - GlobeNewswire
New Clinical Data Shows Cytisinicline Cuts Nicotine Cravings in Phase 3 Trial | ACHV Stock News - Stock Titan
Brokers Offer Predictions for ACHV Q3 Earnings - Defense World
Tower Research Capital LLC TRC Acquires 4,905 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
What is Zacks Small Cap’s Estimate for ACHV Q2 Earnings? - Defense World
Achieve Life Sciences targets NDA submission for cytisinicline in June 2025 as open label study hits key milestones - MSN
Raymond James Financial Inc. Purchases New Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - MarketBeat
Finanzdaten der Achieve Life Sciences Inc-Aktie (ACHV)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.40%
2.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):